Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 3Radiation Injuries 1Quality of Life 1Postoperative Complications 1Low Anterior Resection Syndrome 1Gallbladder Neoplasms 1Fatigue 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Cisplatin 8Radiotherapy 6Fluorouracil 4Paclitaxel 3tislelizumab 2nimotuzumab 2Neoadjuvant Therapy 2Esophagectomy 2Drug Therapy 2Capecitabine 2spartalizumab 1pembrolizumab 1anlotinib 1TP protocol 1Surgical Procedures, Operative 1Radiation 1Oxaliplatin 1Nivolumab 1Leucovorin 1Immunotherapy 1Docetaxel 1Clinical Trials, Phase II as Topic 1Chemoradiotherapy 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Esophageal Squamous Cell Carcinoma × Chemoradiotherapy × Clear all
NCT06861777 2025-03-11

Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3 Not yet recruiting
474 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡